Surgery Timing After Chemotherapy for Ovarian Cancer
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Recruiting
N/A
Interventional Study
Ovarian Epithelial Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 250 (estimated)
- Sponsor
- Alexandria University · Other
Who this trial is looking for
This trial is looking for women with advanced ovarian cancer who are not eligible for immediate surgery. Participants will receive chemotherapy and then have surgery at different times to see which is better for survival.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a female between 18 and 75 years old.
- I have advanced ovarian cancer that is not suitable for immediate surgery.
- I have high-grade serous ovarian, fallopian tube, or peritoneal cancer.
- I have an ECOG performance status of 0 or 1.
- I can have my cancer assessed as resectable after 3 cycles of chemotherapy.
- I have adequate health in terms of blood, lungs, heart, liver, and kidneys.
- My estimated life expectancy is more than 3 months.
- I have a low or moderate level of other health issues.
You may not be able to join if
- I have metastatic ovarian cancer.
- I have a type of ovarian cancer that is not high-grade serous.
- I am pregnant or breastfeeding.
- I have had another invasive cancer in the last 5 years.
- I had a stroke in the last 6 months.
- I have uncontrolled health issues or cannot take chemotherapy.
- My cancer got worse during chemotherapy.
- I have a worsening health performance status.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis. When complete surgery with no macroscopic visible disease is not feasible due to both the spread of the disease and the patient's general condition, neoadjuvant chemother…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Female Patients aged 18 to 75 years.
2. International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV unsuitable for UCS.
3. Histologically confirmed high-grade serous (HGS) ovarian, fallopian tube, or primary peritoneal carcinoma.
4. ECOG performance status: 0 o…
Contacts